3//SEC Filing
Norwest Venture Partners XI, LP 3
Accession 0001209191-19-043154
CIK 0001636422other
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 9:00 PM ET
Size
21.0 KB
Accession
0001209191-19-043154
Insider Transaction Report
Form 3
Norwest Venture Partners XI, LP
10% Owner
Holdings
Series B Convertible Preferred Stock
→ Common Stock (1,442,727 underlying)- (indirect: By Partnership)
Series B Convertible Preferred Stock
→ Common Stock (1,442,727 underlying) - (indirect: By Partnership)
Series E Convertible Preferred Stock
→ Common Stock (424,568 underlying) - (indirect: By Partnership)
Series F Convertible Preferred Stock
→ Common Stock (35,919 underlying) Series D Convertible Preferred Stock
→ Common Stock (471,832 underlying)Series E Convertible Preferred Stock
→ Common Stock (424,568 underlying)Series C Convertible Preferred Stock
→ Common Stock (577,045 underlying)Series F Convertible Preferred Stock
→ Common Stock (35,919 underlying)- (indirect: By Partnership)
Series C Convertible Preferred Stock
→ Common Stock (577,045 underlying) - (indirect: By Partnership)
Series D Convertible Preferred Stock
→ Common Stock (471,831 underlying)
Footnotes (7)
- [F1]The securities shown on Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
- [F2]The Series B Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- [F3]The Series C Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- [F4]The Series D Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- [F5]The Series E Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- [F6]The Series F Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- [F7]The securities shown on Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
Documents
Issuer
Health Catalyst, Inc.
CIK 0001636422
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001534522
Filing Metadata
- Form type
- 3
- Filed
- Jul 23, 8:00 PM ET
- Accepted
- Jul 24, 9:00 PM ET
- Size
- 21.0 KB